Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease

被引:11
|
作者
Patricio, Felipe [1 ]
Parra, Irving [2 ]
Martinez, Isabel [2 ]
Perez-Severiano, Francisca [3 ]
Montes, Sergio [3 ]
Aguilera, Jose [4 ,5 ,6 ]
Daniel Limon, Ilhuicamina [1 ]
Tizabi, Yousef [7 ]
Mendieta, Liliana [2 ]
机构
[1] Benemerita Univ Autonoma Puebla, Fac Ciencias Quim, Lab Neurofarmacol, Puebla, Mexico
[2] Benemerita Univ Autonoma Puebla, Fac Ciencias Quim, Lab Neuroquim, 14 Sur & Ave San Claudio CU, Puebla 72570, Mexico
[3] Inst Nacl Neurol & Neurocirug, Dept Neuroquim, Mexico City 14269, DF, Mexico
[4] Univ Autonoma Barcelona, Fac Med, Inst Neurociencies, Barcelona, Spain
[5] Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Barcelona, Spain
[6] Univ Autonoma Barcelona, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Barcelona, Spain
[7] Howard Univ, Coll Med, Dept Pharmacol, Washington, DC 20059 USA
关键词
Tetanus toxin; 6-Hydroxydopamine; Astrogliosis; Microgliosis; Oxidative stress; Superoxide dismutase; Parkinson's disease; HEAVY-CHAIN; TERMINAL DOMAIN; INTRAMUSCULAR INJECTION; 6-HYDROXYDOPAMINE MODEL; SUBSTANTIA-NIGRA; AXONAL-TRANSPORT; MOTOR BEHAVIOR; FUSION PROTEIN; RAT MODELS; NEURONS;
D O I
10.1007/s12640-018-9990-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Reports indicate that striatal dopaminergic damage induced by 6-hydoxydopamine (6-OHDA) can be blocked by C-terminal domain of tetanus toxin (Hc-TeTx), suggesting possible therapeutic potential of Hc-TeTx in Parkinson's disease (PD). Pramipexole (PPX), a D2/D3 dopaminergic agonist, is currently used in PD treatment. The purpose of this study was to gain some understanding of the actions of each drug, including potential antioxidant and anti-inflammatory effects and importantly, to determine whether the combination of the two drugs would be superior to each alone. Adult male Wistar rats were administered 6-OHDA into the dorsolateral striatum, and the effects of Hc-TeTx fragment (20g/kg i.m. every 24h) for 3days; PPX (1mg/kg p.o., every 12h) for 30days and their combination on various motor and neurochemical parameters were evaluated. Behavioral tests were carried out at 15 and 30days post-treatments. At day 31, the animals were sacrificed and the levels of tyrosine hydroxylase (TH), reflecting dopaminergic activity in both striatum and substantia nigra, were evaluated. In addition, indices of astrogliosis, microgliosis, as well as oxidative stress in the striatum were determined. Both Hc-TeTx and PPX ameliorated the motor and neurochemical deficits induced by 6-OHDA lesion; however, the combination of the two drugs was not superior to each alone. Hence, at concentrations used in this study, no significant advantage in combining Hc-TeTx with PPX was noted. Although the results suggest similar neurochemical effects of the two compounds, further evaluation of different concentrations of Hc-TeTx and PPX as potential intervention in PD is warranted.
引用
收藏
页码:699 / 710
页数:12
相关论文
共 50 条
  • [1] Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson’s Disease
    Felipe Patricio
    Irving Parra
    Isabel Martínez
    Francisca Pérez-Severiano
    Sergio Montes
    José Aguilera
    Ilhuicamina Daniel Limón
    Yousef Tizabi
    Liliana Mendieta
    [J]. Neurotoxicity Research, 2019, 35 : 699 - 710
  • [2] Neuroprotection of Pramipexole in UPS Impairment Induced Animal Model of Parkinson's Disease
    Li, Chao
    Guo, Yuan
    Xie, Wenjie
    Li, Xingang
    Janokovic, Joseph
    Le, Weidong
    [J]. NEUROCHEMICAL RESEARCH, 2010, 35 (10) : 1546 - 1556
  • [3] Neuroprotection of Pramipexole in UPS Impairment Induced Animal Model of Parkinson’s Disease
    Chao Li
    Yuan Guo
    Wenjie Xie
    Xingang Li
    Joseph Janokovic
    Weidong Le
    [J]. Neurochemical Research, 2010, 35 : 1546 - 1556
  • [4] Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease
    Li, C.
    Xie, W.
    Jankovic, J.
    Le, W.
    [J]. MOVEMENT DISORDERS, 2010, 25 (07) : S403 - S403
  • [5] Cost effectiveness of pramipexole in Parkinson's disease in the US
    Hoerger, TJ
    Bala, MV
    Rowland, C
    Greer, M
    Chrischilles, EA
    Holloway, RG
    [J]. PHARMACOECONOMICS, 1998, 14 (05) : 541 - 557
  • [6] Cost Effectiveness of Pramipexole in Parkinson’s Disease in the US
    Thomas J. Hoerger
    Mohan V. Bala
    Clayton Rowland
    Marianne Greer
    Elizabeth A. Chrischilles
    Robert G. Holloway
    [J]. PharmacoEconomics, 1998, 14 : 541 - 557
  • [7] Clinical effectiveness of pramipexole on depressive symptoms in Parkinson's disease
    Parise, V. Fricchione
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S397 - S398
  • [8] The effectiveness of pramipexole and levodopa as an initial treatment for Parkinson's disease
    Oztekin, N. S.
    Oztekin, M. F.
    Polat, R. S.
    Renkliyildiz, B.
    [J]. MOVEMENT DISORDERS, 2007, 22 : S237 - S237
  • [9] The effectiveness of pramipexole and cabergoline as an adjunct to levodopa in Parkinson's disease
    Oztekin, N.
    Oztekin, M. F.
    Sarl-Polat, R.
    Orhan, G.
    Ak, F.
    [J]. PARKINSONISM & RELATED DISORDERS, 2007, 13 : S106 - S107
  • [10] Cost-effectiveness analysis of pramipexole in early Parkinson's disease
    Noyes, K
    Dick, AW
    Holloway, RG
    [J]. VALUE IN HEALTH, 2003, 6 (03) : 274 - 274